Open Journal Systems

Effect of Paclitaxel Combined with Nedaplatin on Serum Tumor Markers, MMP-9 and VEGF Levels in Patients with Endometrial Cancer

Md. Ali Hossain (Manarat International University, Dhaka, Bangladesh)
Noman Hossain (Beijing Institute of Technology, Dhaka, Bangladesh)

Abstract


Objective. To evaluate the effects of paclitaxel combined with nedaplatin on serum tumor markers, MMP-9 and VEGF levels in patients with endometrial cancer. Methods. The clinical data of 104 patients with endometrial cancer diagnosed and treated by the Obstetrics and Gynecology Hospital of Nanjing Medical University from January 2018 to January 2019 were retrospectively analyzed. The root randomized number method was divided into two groups. The control group (50 cases) received conventional cisplatin + doxorubicin + cyclophosphamide (CAP) regimen chemotherapy; the study group (54 patients) received paclitaxel + nedaplatin (TP) chemotherapy Interventions were used to compare the changes of tumor markers before and after chemotherapy, the changes of MMP-9 and VEGF levels and the adverse reactions after chemotherapy. Results After chemotherapy, serum tumor markers, MMP-9 and VEGF levels were significantly decreased in the two groups, but the overall level of chemo- therapy in the study group was significantly lower than that in the control group, with statistically differences (P<0.05). The incidence of drug side effects in the study group was significantly lower than that of the control group, with statistically significant difference (P<0.05) . Conclusions Paclitaxel + nedaplatin can significantly reduce the levels of MMP-9, VEGF and tumor markers in patients with endometrial cancer, and can effectively prevent the occurrence of toxic side effects, which is worthy of promotion.


Keywords


Endometrial cancer; Nedaplatin; Paclitaxel; Serum tumor markers; Vascular endothelial growth factor (VEGF)

Full Text:

PDF

References


Chen H H, Wang X H, Li S, et al. Effects of chemotherapy combined with surgery on serum TSGF, PRL, HE4 and inflammatory factors in patients with endometrial carcinoma [J]. Journal of Hainan Medical College, 2017,23 (5) : 705-708.

Ren C M, Cui S Y. Therapeutic efficacy of TC chemotherapy combined with radiotherapy for postoperative tumor recurrence in high-risk endometrial carcinoma [J]. Journal of Applied Cancer, 2018,33 (9) : 1472-1474.

[3] Mikulova V,Jancikova M,Tesarova P,et al. Abstract P5-08-45: The predictive potential of metastatic serum markers and circulating tumor cells in advanced HER2-positive breast cancer patients-Focused on CNS metastases [J]. Cancer Research,2016,76( 4) : 45.

[4]Zhou Q, Wu X H, Liu J H, et al. Diagnosis and treatment of endometrial carcinoma [J]. Chinese Journal of Applied Gynecology and Obstetrics, 2018,34 (8) : 52-58.

[5]Liang J Y, Yang M N. Evaluation of tumor load and toxic side effects of nedaplatin combined with paclitaxel liposome and paclitaxel in advanced esophageal cancer [J]. Journal of Hainan Medical College, 2017,23 (8) : 1102-1105.

Guan F J. Effects of chemoradiotherapy on serum tumor markers, MMP-9, VEGF and inflammatory factors in patients with endometrial carcinoma after operation [J]. Journal of Hainan Medical College, 2017,23 (17) : 2404-2407.

Chen H H, Wang X H, Li S, et al. Effects of chemotherapy combined with surgery on serum TSGF, PRL, HE4 and inflammatory factors in patients with endometrial carcinoma [J]. Journal of Hainan Medical College, 2017,23 (5) : 705-708.

Cui P H, Wang H M, Zhang Y J, et al. Effect of laparoscopic and open surgery on serum tumor markers, coagulation function and immune function in patients with early endometrial carcinoma [J]. Journal of Hainan Medical College, 2017,23 (15) : 2109-2112.

Shang H, Wang Y M, Zhang H S. Clinical efficacy and safety of paclitaxel combined with nedaplatin in the treatment of local late non-small cell lung cancer [J]. Journal of Clinical Pulmonary Surgery, 2017,22 (10) : 1870-1873.

[10] Klimiuk PA,Domyslawska I,Sierakowski S,et al. AB0447 regulation of serum matrix metalloproteinases and tissue inhibitor of metallopro- teinases-1 following rituximab therapy in patients with rheumatoid ar- thritis refractory to anti-tumor necrosis factor blockers [J]. Rheumatol- ogy International,2015, 35( 4) : 749-755.

Wang J, Luo X Q, Chen S C. Effect of paclitaxel combined with nedaplatin arterial interventional embolization on the density of microvascular and lymphatic vessels in cervical squamous cell carcinoma [J]. Applied Pharmacology and Clinical Practice, 2016,19 (3) : 287-291.

Zhu S Y, Tan J, Zhang C X, et al. Effects of Nedaplatin on serum HE4, CA125, CA19-9, AFP, CEA and T cell subsets in patients with advanced ovarian cancer [J]. Journal of Hainan Medical University, 2016,22 (15) : 1737-1740.

Li Q P, Wang W. Clinical observation of liposomal paclitaxel combined with nedaplatin and first-line paclitaxel combined with nedaplatin in advanced non-small cell lung cancer [J]. Central South Journal of Medical Science, 2017,45 (5) : 513-515.

Li X, Chen X, Song N Y, et al. Intraperitoneal infusion of nedaplatin combined with paclitaxel chemotherapy for advanced ovarian cancer and its effect on the expression of Toll-like receptor and breast cancer susceptibility gene [J]. Chinese Medicine, 2016,11 (5) : 729.

Liu J H, Qiao J F, Hua W W. Diagnostic effect of transvaginal ultrasonography on myometrial invasion and pathological stage of endometrial carcinoma [J]. Chinese Journal of Sexual Science, 2017,26 (8) :39-42.

Liu L H, Cai J D, Liu Y Q, et al. Effects of paclitaxel and nedaplatin on local advanced esophageal cancer [J]. China Medical Review, 2017(23) : 80-83.



DOI: http://dx.doi.org/10.30564/amor.v6i5.288

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Md. Ali Hossain, Noman Hossain

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.